## Context

The provider already exposes the contract surface required for a MyPrivateAgent document RAG trial: health, capabilities, catalog, RAG sources, RAG retrieval, graph schema discovery, and a planned graph query boundary. Prior Phase 10-18 artifacts also simplified the access gate so only primitive provider access signals block the minimal trial path.

Phase 24 should therefore close readiness, not add another evidence layer. The report will read current local evidence and produce a small caller-facing conclusion.

## Goals / Non-Goals

**Goals:**
- Produce one provider-side closure report for document RAG repo-side trial readiness.
- Classify the outcome as `ready`, `review`, or `blocked`.
- Emit a caller decision as `go`, `review`, or `blocked`.
- Preserve a short list of required primitive signals and review-only context signals.
- Export JSON and Markdown artifacts for handoff.

**Non-Goals:**
- Do not execute the MyPrivateAgent trial.
- Do not create source-to-agent bindings or caller audit records.
- Do not promote Qdrant, BGE-M3, hybrid retrieval, reranking, or GraphRAG execution.
- Do not start a server, run live deployment validation, rebuild indexes, or download models.
- Do not change provider HTTP contracts.

## Decisions

- Reuse current local evidence artifacts instead of adding new runtime probes.
  - Rationale: provider contract smoke and Phase 10/11 access smokes already exercise the integration-critical endpoints.
  - Alternative considered: a new live HTTP smoke. Rejected because live URL validation is optional Phase 6 evidence and not required for local repo-side trial readiness.

- Treat primitive access signals as the blocking gate.
  - Rationale: Phase 18 intentionally simplified the gate to provider contract smoke plus Phase 10/11 primitive smokes.
  - Alternative considered: requiring all handoff/review reports to be ready. Rejected because that would restart evidence-chain expansion.

- Keep Phase 16 and handoff evidence as review context.
  - Rationale: they help humans understand posture but should not block a minimal trial if primitive signals pass.
  - Alternative considered: ignoring review context entirely. Rejected because the closure report should still make open review notes visible.

## Risks / Trade-offs

- Review context may remain `review` while the trial gate is `ready` -> The report will make this explicit and return `go` only when primitive access signals pass.
- Local evidence can drift after code changes -> The export script and tests provide a focused refresh path.
- The report might be mistaken for production approval -> Notes and non-goals explicitly preserve `keep_runtime_defaults` and caller-owned trial execution.
